Journal of translational medicine · 2026
From metabolic dysregulation to clinical alert: a novel panel of biomarkers for staging alcohol-associated liver disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Haonan, Zhang Xiaojia, Tian Lugao, Cheng Zilu, Gao Wenkang, Yang Ye, Li Zexuan, Che Jiake, Zhu Yuanqing, Tan Yupin, Yang Yue, Wang Xinyang, Wang Shuyan, Yuan Yonggang, Cao Zhuang, Zhao Yunfei, Du Xiaotong, Liu Jiahao, Liao Nanfei, Chen Yue, Yan Shengqi, Yang Ling, Jiang Lu, Hou Xiaohua, Xu Keshu, Song Yuhu, Chu Huikuan
Аннотация
BACKGROUND AND AIM: ALD is among the most prevalent chronic liver disorders with rising global incidence, the aim of our study is to evaluate the effect of metabolites in the progress of ALD, and build a prediction model for ALC.
METHODS: A total of 161 subjects were prospectively enrolled and classified into HC, AUD, AH, ALC. Plasma samples underwent untargeted LC-MS/MS metabolomics analysis. Data were split into training, validation and test sets at a 6:2:2 ratio. Partial least squares discriminant analysis and random forest were employed for feature selection, followed by logistic regression to build metabolite-based and metabolite-plus-clinical composite models. Discrimination was evaluated by AUC, sensitivity, specificity and accuracy.
RESULTS: Metabolomic profiles showed progressive separation among groups (Q² > 0.65 for all PLS-DA models). Five metabolites (Vecuronium, N-Docosahexaenoyl Cysteine, 7-Acetylintermedine, Hymenoxon, E-3174) were identified as the most influential features for distinguishing ALC from HC, yielding an AUC of 0.986 (95% CI: 0.969-0.999) in the validation set and 100% accuracy in the test set. Integration of these metabolites with AST further elevated the AUC to 0.998 with 96.70% sensitivity and 100% specificity. Similarly, a five-metabolite panel plus PT achieved perfect accuracy (AUC = 0.964) in discriminating ALC from AH.
CONCLUSIONS: We delineate stage-specific metabolic fingerprints of ALD and present robust, non-invasive models for early identification of cirrhosis. Incorporating metabolomic biomarkers with routine clinical variables markedly improves diagnostic precision and offers a practical tool for risk stratification and personalized management of alcohol-related liver disease.
METHODS: A total of 161 subjects were prospectively enrolled and classified into HC, AUD, AH, ALC. Plasma samples underwent untargeted LC-MS/MS metabolomics analysis. Data were split into training, validation and test sets at a 6:2:2 ratio. Partial least squares discriminant analysis and random forest were employed for feature selection, followed by logistic regression to build metabolite-based and metabolite-plus-clinical composite models. Discrimination was evaluated by AUC, sensitivity, specificity and accuracy.
RESULTS: Metabolomic profiles showed progressive separation among groups (Q² > 0.65 for all PLS-DA models). Five metabolites (Vecuronium, N-Docosahexaenoyl Cysteine, 7-Acetylintermedine, Hymenoxon, E-3174) were identified as the most influential features for distinguishing ALC from HC, yielding an AUC of 0.986 (95% CI: 0.969-0.999) in the validation set and 100% accuracy in the test set. Integration of these metabolites with AST further elevated the AUC to 0.998 with 96.70% sensitivity and 100% specificity. Similarly, a five-metabolite panel plus PT achieved perfect accuracy (AUC = 0.964) in discriminating ALC from AH.
CONCLUSIONS: We delineate stage-specific metabolic fingerprints of ALD and present robust, non-invasive models for early identification of cirrhosis. Incorporating metabolomic biomarkers with routine clinical variables markedly improves diagnostic precision and offers a practical tool for risk stratification and personalized management of alcohol-related liver disease.